Strategic investments Sophisticated funding interest from major asset managers like BlackRock indicating strong institutional appetite and potential for partnerships or co-investment discussions in health tech or life sciences ventures.

Clinical momentum Active advancement in neuroscience and epilepsy therapeutics with multiple Phase 3 data presentations and NDA timelines suggests opportunities to align with clinical research organizations, CROs, and specialty pharma units seeking parallel services or commercialization partnerships.

Public market visibility Ongoing investor communications and inducement equity grants point to a company with rising market profile; sales motions could target strategic financers, advisory firms, and healthcare-focused investment banks for consulting and sponsored research or licensing deals.

Expansion potential Pipeline focus on azetukalner and potential ex-US expansion scenarios implies demand for cross-border regulatory consulting, market access, and distribution partnerships in international regions.

Operational scale Revenue trajectory in the reported range and a sizable cash runway into 2029 create opportunities to propose enterprise-grade technology, data analytics, and commercialization support solutions to scale marketing and market access activities.